RecruitingNCT06813742
18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
A Prospective Exploratory Study Evaluating the Diagnostic Usefulness of 18F-mFBG PET Imaging in Pheochromocytoma
Sponsor
First Affiliated Hospital of Zhejiang University
Enrollment
80 participants
Start Date
May 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria3
- Aged 30-80 years old, primary school or above, with a regular caregiver;
- Clinically diagnosed patients with pheochromocytoma;
- Can provide informed consent, can understand and comply with the study requirements.
Exclusion Criteria7
- Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system;
- Uncontrolled hypertension or high-risk BP (i.e., systolic BP > 180 mmHg or diastolic BP > 110 mmHg);
- Patients with mental disorders or primary affective disorders;
- Unable to understand and adhere to the study protocol or provide informed consent;
- Contraindications to PET imaging (including pregnant women, lactating women, and women of childbearing age with recent childbearing plans, etc.);
- Allergy to imaging agents;
- Patients who were unable to cooperate with PET scanning, such as hypoglycemia, severe pain or tremor.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUG18F-MFBG
Patients with pheochromocytoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06813742
Related Trials
Diagnosis of Pheochromocytoma
NCT000048471 location
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
NCT0563661819 locations
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
NCT032060601 location
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
NCT001072891 location
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations